New medications to fight the altitude sickness suffered by mountain climbers promise to aid peak performance. But the same drugs could also yield new treatments for people with breathing disorders. Brendan Borrell meets one man at DARPA, the US Defense Department's research agency, who's trying to move mountains for a new therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
West, J.B. Science 223, 784–788 (1984).
Dunin-Bell, O. & Boyle, B. High Alt. Med. Biol. 10, 293–296 (2009).
Irwin, D.C. et al. Free Radic. Biol. Med. 47, 55–61 (2009).
Erzurum, S.C. et al. Proc. Natl. Acad. Sci. USA 104, 17593–17598 (2007).
Moya, M.P., Gow, A.J., Califf, R.M., Goldberg, R.N. & Stamler, J.S. Lancet 360, 141–143 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Borrell, B. Mountains to Climb. Nat Med 16, 1176–1179 (2010). https://doi.org/10.1038/nm1110-1176
Published:
Issue date:
DOI: https://doi.org/10.1038/nm1110-1176
